Today marks the one year anniversary of Major League Baseball's largest suspension sentencing, where more than a dozen players' seasons were halted due to their doping ties with Biogenesis.
Coincidentally, today is also the day that Anthony Bosch, founder of the infamous Biogenesis clinic, has surrendered to the federal Drug Enforcement Administration.
According to ESPN, Bosch and his attorney drove to the DEA's regional office in Weston, FL this morning, where he was hit with the charge of conspiracy to distribute performance-enhancing drugs.
Bosch, a self-described biochemist, is believed to be the ringleader in what ESPN calls, "the largest performance-enhancing drug scandal in American sports history." To date, Major League Baseball has spent more money looking into Biogenesis than every one of their previous investigations put together.
RELATED: Source: MLB Gave A-Rod Testosterone OK in 2007
With nearly 20 MLB players having been suspended because of the league's findings, its probing has certainly had an impact. And when the league suspends stars like Alex Rodriguez, who is serving a 162-game suspension, and Ryan Braun, who served his 65-game suspension last summer, that impact gets noticed.
However, catching more big leaguers using PEDs isn't a focus with Bosch now in custody.
As reported by the New York Daily News, the grand jury in the Bosch case is "believed to be focused on who funded Bosch’s operation and whether Bosch supplied sports drugs to parents, who in turn handed them over to their teenage children," rather than catching more potential professional users.
RELATED: Report: HGH Use Among Teens Doubles to 11 Percent
Clinic records revealed the names of at least 15 high school or college athletes who were Bosch patients, most of whom received PEDs. The parents or attorneys for several of the players either denied any involvement with Bosch or that the teenager took a banned substance, although the attorney for at least one athlete confirmed the PED regimen prescribed for his client.
Andrew Brandt is an editorial intern with Athletic Business.
